Indeed, researchers have demonstrated that the usage of antibodies against latent TGF-β-binding protein 4 (LTBP4) can decrease LTBP4 proteolytic cleavage, thereby reducing release of TGF-β and alleviating muscle fibrosis in patients with DMD [59]. This evidence concerns the gene LTBP4 and Duchenne muscular dystrophy.